GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization | GenomeWeb

Originally published Oct. 26.

By Turna Ray

Continuing to aggrandize its presence in the personalized medicine space, GE Healthcare announced plans last week to scoop up Clarient for around $580 million.

The acquisition gives GE access to an array of molecular tests in oncology, a clinical laboratory for providing diagnostic services, and markers that can lead to the development of companion diagnostics for therapies treating leukemia, as well as breast, prostate, lung, and colon cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.